Earnings summaries and quarterly performance for Corteva.
Executive leadership at Corteva.
Charles V. Magro
Detailed
Chief Executive Officer
CEO
DP
David P. Johnson
Detailed
Executive Vice President, Chief Financial Officer
JA
Jennifer A. Johnson
Detailed
Senior Vice President, Chief Legal Officer
RD
Robert D. King
Detailed
Executive Vice President, Crop Protection Business Unit
SR
Samuel R. Eathington
Detailed
Executive Vice President, Chief Technology & Digital Officer
Board of directors at Corteva.
DC
David C. Everitt
Detailed
Director
GR
Gregory R. Page
Detailed
Chair of the Board
JP
Janet P. Giesselman
Detailed
Director
KH
Karen H. Grimes
Detailed
Director
KJ
Kerry J. Preete
Detailed
Director
KA
Klaus A. Engel
Detailed
Director
LA
Lamberto Andreotti
Detailed
Director
MM
Marcos M. Lutz
Detailed
Director
MO
Michael O. Johanns
Detailed
Director
NR
Nayaki R. Nayyar
Detailed
Director
PJ
Patrick J. Ward
Detailed
Director
Research analysts who have asked questions during Corteva earnings calls.
ER
Edlain Rodriguez
Mizuho Securities
8 questions for CTVA
Also covers: ALB, BALL, CCK +6 more
Kevin McCarthy
Vertical Research Partners
8 questions for CTVA
Also covers: ALB, ALTM, APD +17 more
Vincent Andrews
Morgan Stanley
8 questions for CTVA
Also covers: ALB, APD, AVNT +20 more
Joel Jackson
BMO Capital Markets
7 questions for CTVA
Also covers: AGCO, ALB, ALTM +11 more
Patrick Cunningham
Citigroup
7 questions for CTVA
Also covers: ALB, APD, AXTA +17 more
DB
David Begleiter
Deutsche Bank
6 questions for CTVA
Also covers: ALB, APD, ASH +24 more
Kristen Owen
Oppenheimer & Co. Inc.
6 questions for CTVA
Also covers: , AGCO, AVNT +15 more
Matthew Deyoe
Bank of America
5 questions for CTVA
Also covers: APD, AXTA, CF +12 more
AY
Aleksey Yefremov
KeyBanc Capital Markets
4 questions for CTVA
Also covers: ALB, ALTM, AXTA +14 more
AV
Arun Viswanathan
RBC Capital Markets
4 questions for CTVA
Also covers: ALB, AMBP, AMCR +25 more
CP
Chris Parkinson
Wolfe Research, LLC
4 questions for CTVA
Also covers: ASH, AXTA, CCK +7 more
CP
Christopher Parkinson
Wolfe Research
4 questions for CTVA
Also covers: ALB, APD, ASH +17 more
Duffy Fischer
Goldman Sachs
4 questions for CTVA
Also covers: APD, AXTA, CC +9 more
JZ
Jeffrey Zekauskas
JPMorgan Chase & Co.
4 questions for CTVA
Also covers: ALB, AMCR, APD +31 more
JS
Josh Spector
UBS Group
4 questions for CTVA
Also covers: ALB, AMBP, APD +28 more
Frank Mitsch
Fermium Research
3 questions for CTVA
Also covers: AVNT, CE, DD +13 more
Joshua Spector
UBS
3 questions for CTVA
Also covers: ALB, AMBP, APD +37 more
AV
Aaron Viswanathan
RBC Capital Markets
2 questions for CTVA
Also covers: AMCR
AV
Aleksey V. Yefremov
KeyBanc Capital Markets Inc.
2 questions for CTVA
Also covers: RPM
BT
Ben Thayer
Barclays
2 questions for CTVA
CJ
Carol Jiang
Jefferies
2 questions for CTVA
DR
Dan Rizwan
Jefferies
2 questions for CTVA
JZ
Jeff Zekauskas
JPMorgan
2 questions for CTVA
Also covers: DOW, OLN, PPG
Michael Sison
Wells Fargo
2 questions for CTVA
Also covers: ALB, APD, ASH +16 more
Richard Garchitorena
Wells Fargo
2 questions for CTVA
Also covers: CF, DOW, FMC +2 more
Steve Byrne
Bank of America
2 questions for CTVA
Also covers: ADM, APD, AXTA +19 more
ER
Edlain Rodriguez
Mizuho Securities USA LLC
1 question for CTVA
Emily Fusco
Deutsche Bank
1 question for CTVA
Also covers: APD, CBT, FUL +3 more
PF
Patrick Fischer
Goldman Sachs
1 question for CTVA
Also covers: APD, AXTA, CC +8 more
Rachel Leon
Citigroup Inc.
1 question for CTVA
SL
Salvo Latiano
Bank of America
1 question for CTVA
Recent press releases and 8-K filings for CTVA.
Corteva reports Q4 2025 earnings results
CTVA
Earnings
Guidance Update
- Net sales of $3.91 billion in Q4 2025, down 2% year-over-year; GAAP Operating EBITDA was $446 million (–15%), with margin at 11.4% (–179 bps).
- Seed net sales of $1.74 billion (–2%), with Seed Operating EBITDA up 33% to $124 million; Crop Protection Operating EBITDA declined to $360 million from $461 million in Q4 2024.
- Q4 Operating EPS of $0.22 (–31%) versus $0.32 in Q4 2024; GAAP EPS loss of $0.80 per share versus a loss of $0.08.
- Full-year Operating EPS of $3.34 (up from $2.57 in FY 2024), driven by volume/price gains and cost savings; FY 2026 guidance calls for low-to-mid single-digit revenue growth and $4.0–$4.2 billion of Operating EBITDA.
3 days ago
Corteva reports Q4 2025 results and 2026 guidance
CTVA
Earnings
Guidance Update
Legal Proceedings
- 2025 organic sales rose 4% with operating EBITDA up 14% to $3.85 billion and margins expanding above 22%; free cash flow improved by $1.2 billion to $2.9 billion.
- 2026 guidance set at $4.0–4.2 billion operating EBITDA (+7%) and $3.45–3.70 operating EPS, targeting $500 million of share repurchases in H1.
- Separation on track for a Q4 2026 spin-off with net dyssynergies of $100 million (of which $50 million is in 2026 guidance).
- Settled litigation with Bayer, achieving royalty neutrality in 2026, accelerating corn licensing to 2027, entering U.S. cotton licensing, and unlocking $1 billion upside over the next decade.
3 days ago
Corteva announces Q4 2025 results
CTVA
Earnings
Guidance Update
Legal Proceedings
- Q4 organic sales declined 4%, while full-year organic sales grew 4%; full-year operating EBITDA rose 14% to $3.85 billion with margins over 22%, and free cash flow improved by $1.2 billion to $2.9 billion.
- 2026 guidance set operating EBITDA at $4.0–4.2 billion (midpoint $4.1 billion, +7% y/y) and operating EPS at $3.45–$3.70; the company expects 60% of sales and 85% of EBITDA in H1 2026 and plans $500 million of share repurchases in the period.
- Key 2026 assumptions include slight seed price gains offset by low-single-digit crop protection price declines, flat seed volumes, mid-single-digit crop protection volume growth, $120 million net royalty improvement, $200 million productivity benefits, $80 million tariff headwind, and $75 million FX tailwind.
- Reached a comprehensive resolution with Bayer, paying $610 million in 2025 to resolve litigation, accelerate royalty neutrality to 2026, and unlock ~$1 billion of licensing income over the next decade; accelerates corn licensing to 2027, next-gen trait licensing by 2030, and grants cotton licensing rights.
- Returned $1.5 billion to shareholders in fiscal 2025 via dividends and buybacks, with continued focus on capital return as separation progresses.
3 days ago
Corteva announces Q4 2025 results and provides 2026 guidance
CTVA
Earnings
Guidance Update
Legal Proceedings
- Separation plan on track for the second half of 2026, most likely in Q4, with a global CEO search, Form 10 filings, board appointments, and Investor Day in mid-September 2026.
- Q4 2025 organic sales down 4%; seed pricing +3% vs. volume –8%, crop protection volume –2% and price –1%. Full year organic sales +4%, operating EBITDA up 14% to $3.85 billion and margins above 22%.
- Free cash flow rose by $1.2 billion to $2.9 billion in 2025, with a $610 million commitment paid toward Bayer resolution.
- 2026 guidance: operating EBITDA of $4.0–4.2 billion (+7% at midpoint), EPS of $3.45–$3.70, targeting $500 million of share repurchases in H1 2026 and maintaining the quarterly dividend.
- Resolved Bayer seed litigation, securing freedom to operate, achieving royalty neutrality in 2026 (two years early), accelerating corn licensing to 2027, entering U.S. cotton licensing, and underpinning an expected $1 billion of aggregate earnings upside over ten years.
3 days ago
Corteva reports Q4 and full-year 2025 results
CTVA
Earnings
Guidance Update
Legal Proceedings
- Q4 2025 GAAP net sales were $3.91 B with a GAAP loss from continuing operations of $537 M (EPS $(0.80)); non-GAAP organic sales were $3.82 B, operating EBITDA $446 M, and operating EPS $0.22.
- FY 2025 net sales rose 3% to $17.40 B, GAAP EPS was $1.75, and non-GAAP operating EBITDA reached $3.85 B (operating EPS $3.34).
- Generated $3.5 B in operating cash flow (+51%) and $2.9 B in free cash flow (+69%), supporting over $1.5 B returned to shareholders in 2025.
- Full-year 2026 guidance calls for operating EBITDA of $4.0–$4.2 B and operating EPS of $3.45–$3.70.
- Reached comprehensive litigation resolution with Bayer to accelerate licensing and freedom to operate, with a $610 M cash outflow expected in Q1 2026.
3 days ago
Corteva reports Q4 and full-year 2025 results
CTVA
Earnings
Guidance Update
- Q4 2025 results included net sales of $3.91 B, a GAAP loss per share of $(0.80), and non-GAAP EPS of $0.22
- Full-year 2025 net sales were $17.40 B (up 3% vs. 2024); non-GAAP Operating EBITDA was $3.85 B and Operating EPS was $3.34
- Cash provided by operations was $3.5 B (+51%) with free cash flow of $2.9 B (+69%), supporting over $1.5 B returned to shareholders
- 2026 guidance calls for Operating EBITDA of $4.0–4.2 B and Operating EPS of $3.45–3.70 per share
- The company remains on track to complete its planned separation in the second half of 2026
3 days ago
Corteva and bp launch Etlas biofuel feedstock JV
CTVA
New Projects/Investments
Management Change
- Corteva and bp have formed a 50:50 joint venture, Etlas, to produce oil from canola, mustard and sunflower crops as feedstock for sustainable aviation fuel (SAF) and renewable diesel (RD).
- Etlas targets 1 million metric tonnes of feedstock per year by the mid-2030s (enough to yield over 800,000 tonnes of biofuel) and plans to begin initial supply in 2027.
- The venture will source intermediate crops grown on existing cropland between main food seasons, enhancing soil health and providing farmers with new revenue streams.
- Ignacio Conti will serve as CEO and Gaurav Sonar as Chair of the Board of Directors for Etlas.
Jan 7, 2026, 11:00 AM
Corteva forms JV with Hexagon Bio for nature-inspired crop protection
CTVA
New Projects/Investments
- Corteva and Hexagon Bio launched a multi-million-dollar joint venture to accelerate development of nature-inspired crop protection solutions.
- The JV merges Corteva’s billion-dollar nature-inspired crop protection franchises and bacterial natural product discovery capabilities with Hexagon Bio’s natural-product discovery platform.
- It is the first agriculture-sector JV for Hexagon Bio and the first pharmaceutical JV for Corteva, targeting cross-industry pipeline advancement.
- The JV is facilitated through Corteva Catalyst, which has partnered with 11 companies since its March 2024 launch.
Dec 16, 2025, 1:00 PM
Corteva reports Q3 2025 earnings
CTVA
Earnings
Guidance Update
- Q3 2025 net sales were $2.6 B, up 13% YoY, and organic sales grew 11% on strong seed and crop protection volumes.
- Q3 Operating EBITDA turned positive at $49 M vs. a $(100) M loss a year ago, with operating margin expanding to 1.9% from –4.3% (+617 bps).
- YTD net sales reached $13.5 B (+4%), organic sales were +6%, and YTD Operating EBITDA was $3.4 B (+19%) with a 25.2% margin (+317 bps); Corteva raised FY 2025 Operating EBITDA guidance to $3.80–$3.90 B (+14% at midpoint).
- On track to complete the separation into two public companies—New Corteva and SpinCo—in 2H 2026, creating focused platforms in crop protection, plant health, and advanced genetics.
Nov 5, 2025, 2:00 PM
Corteva announces Q3 2025 results
CTVA
Earnings
Guidance Update
Product Launch
- Intent to separate Corteva into two public companies (seed and crop protection) by second half 2026 to unlock growth potential in each segment.
- Q3 organic sales rose 11% and volumes 12% year-over-year; year-to-date operating EBITDA reached $3.4 billion (+19%) with a margin above 25% (+320 bps).
- Full-year operating EBITDA guidance raised to $3.8 billion–$3.9 billion (midpoint +14% YoY), with over $600 million in controllable benefits now expected for 2025.
- Product launch: unveiled Varpalgo, a next-generation insecticide targeting chewing pests, expected in the early 2030s and forecasted to peak at $750 million in revenue.
Nov 5, 2025, 2:00 PM
Quarterly earnings call transcripts for Corteva.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more